NBP
NovaBridge Biosciences
Biotechnology · Healthcare · United States
1.20
close · 2026-10-30
value
26
cheaper than peers26
quality
77
stronger fundamentals77
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.69× | 90 |
| cash flow yield, latest year | -14.9% | 54 |
| earnings yield, 1 year ago | -23.1% | 53 |
| earnings yield, latest year | -40.4% | 39 |
| cash flow yield, 1 year ago | -38.0% | 33 |
| cash flow yield, 3 years ago | -37.3% | 29 |
| cash flow yield, 2 years ago | -52.6% | 23 |
| earnings yield, 2 years ago | -195.2% | 19 |
| earnings yield, 3 years ago | -354.6% | 8 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -40.9% | 73 |
| debt to equity | 1.3% | 67 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $139M |
| free cash flow | -$37.1M |
| employees | 30 |
| first trade | 2020-01-17 |
| next earnings | 2026-08-20 |
| fundamentals updated | 2026-08-20 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.48 | -0.28 | -2.33 | -4.24 |
| free cash flow | -$20.6M | -$52.7M | -$72.9M | -$51.7M |
| net income | -$46.3M | -$22.2M | -$207.7M | -$371.1M |
| revenue | $0 | $0 | $632,000 | -$1.6M |
| unusual items | -$1.8M | -$5.4M | -$32.2M | -$28.7M |